Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $20.57

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $20.57.

A number of research firms recently weighed in on STOK. TD Cowen upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. Canaccord Genuity Group decreased their price target on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, May 7th. Finally, Wedbush raised their target price on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th.

Stoke Therapeutics Stock Down 3.6 %

STOK opened at $14.23 on Thursday. The firm has a 50-day simple moving average of $13.66 and a two-hundred day simple moving average of $9.10. The company has a market capitalization of $741.68 million, a PE ratio of -5.90 and a beta of 0.88. Stoke Therapeutics has a 52 week low of $3.35 and a 52 week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.03. The business had revenue of $4.22 million for the quarter, compared to the consensus estimate of $3.33 million. As a group, sell-side analysts expect that Stoke Therapeutics will post -2.3 earnings per share for the current year.

Insider Activity at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 5,126 shares of the stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $13.20, for a total value of $67,663.20. Following the completion of the sale, the general counsel now directly owns 2,598 shares of the company’s stock, valued at approximately $34,293.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, General Counsel Jonathan Allan sold 5,126 shares of Stoke Therapeutics stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $13.20, for a total transaction of $67,663.20. Following the completion of the sale, the general counsel now owns 2,598 shares in the company, valued at approximately $34,293.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Skorpios Trust sold 3,600,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total value of $41,760,000.00. Following the transaction, the insider now directly owns 10,843,681 shares in the company, valued at $125,786,699.60. The disclosure for this sale can be found here. 11.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Sherbrooke Park Advisers LLC bought a new position in shares of Stoke Therapeutics in the 3rd quarter worth $48,000. Corton Capital Inc. acquired a new position in shares of Stoke Therapeutics during the third quarter valued at approximately $58,000. Public Employees Retirement System of Ohio acquired a new position in shares of Stoke Therapeutics during the third quarter valued at approximately $64,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Stoke Therapeutics in the first quarter valued at approximately $141,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Stoke Therapeutics by 86.2% in the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after purchasing an additional 6,636 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.